NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +71.15% and +486.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?